NIH and partners to start HIV vaccine trial in Europe and America
Category: #health  By Pankaj Singh  Date: 2019-07-17
  • share
  • Twitter
  • Facebook
  • LinkedIn

NIH and partners to start HIV vaccine trial in Europe and America
  • A unit of Janssen Pharmaceutical Companies of Johnson & Johnson would be sponsoring the Mosaico trial.
  • A complementary study involving women is also currently under process in southern Africa.

The National Institutes of Health (NIH), a biomedical research unit of the U.S. Department of Health and Human Services, and its partners recently announced their plans to commence a Phase 3 clinical trial that would test the efficacy of an investigational HIV vaccine.

Reports cite, the trial would take place across a number or clinical research sites, including Europe, South America and North America. The proposed trial has been dubbed Mosaico or HPX3002/HVTN 706 and is set to launch soon.

According to reports, Janssen Vaccines & Prevention, B.V., a unit of Janssen Pharmaceutical Companies of Johnson & Johnson, would be sponsoring the Mosaico trial. The study would enroll 3,800 HIV negative transgenders and men that are sexually active with other transgenders or/and men. Along with the U.S., other countries such as Italy, Mexico, Poland, Peru, Argentina, Spain and Brazil would also be participating in the study.

The Director of NIAID Anthony S. Fauci, M.D., stated that the organization is committed towards the creation of an effective and safe HIV vaccine that would help people that are most vulnerable to HIV across globe. Dr. Fauci further added that ensuring evaluation of such investigational vaccines among a diverse demographic is crucial for attaining the goal.

All trial participants would be offered a complete HIV prevention package and would be randomly assigned either the investigational HIV vaccine or placebo. The investigational vaccines would be administered at four separate time points over a years’ worth of time.

According to reports, the Mosaico trial would be the third HIV vaccine efficacy clinical study in progress across the world. The NIH’s National Institute of Allergy and Infectious Diseases (NIAID) would be providing funding support to the clinical trial which is expected to be open for enrollment in the U.S. by the end of the year.

Source Credits: https://www.nih.gov/news-events/news-releases/nih-partners-launch-hiv-vaccine-efficacy-trial-americas-europe



About Author

Pankaj Singh

Email: [email protected]   

Pankaj Singh

Pankaj Singh Develops content for Market Size Forecasters, Algosonline, and a couple of other platforms. A Post Graduate in Management by qualification, he worked as an underwriter in the UK insurance domain before deciding to switch his field of profession. With exp...

Read More

More News By Pankaj Singh

RADLogics obtains FDA's approval for AI-based chest X-Ray App
RADLogics obtains FDA's approval for AI-based chest X-Ray App
By Pankaj Singh

RADLogics Inc., a healthcare software company developing AI-powered solutions has reportedly received 510(k) clearance from the US FDA (Food and Drug Administration) for its latest AI-Powered chest X-ray pneumothorax a...

CDE of China NMPA clears I-Mab’s application for lemzoparlimab
CDE of China NMPA clears I-Mab’s application for lemzoparlimab
By Pankaj Singh

Clinical stage biopharmaceutical major, I-Mab, has reportedly announced that it has received the clearance of the Center for Drug Evaluation of the China National Medical Products Administration for its IND application...

Aoyuan Healthy to acquire 55% equity interest in Liantianmei
Aoyuan Healthy to acquire 55% equity interest in Liantianmei
By Pankaj Singh

Aoyuan Healthy Life Group Company Ltd., a renowned commercial property operation service and property management service provider based in China, has reportedly announced that Guangdong Xinyuerong Industrial Investment...